HeyJaredMichael Monostra
- Indexed articles, last 90 days
- 54
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Healio
- Top 500K sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Survodutide induces âimpressiveâ amount of weight loss in type 2 diabetes and obesity (opens the original)
Read excerpt
A once-weekly GLP-1/glucagon dual agonist reduced body weight by up to 9.8% at 76 weeks for adults with type 2 diabetes and overweight or obesity, according to findings from the SYNCHRONIZE-2 trial. As Healio previously reported, survodutide (Boehringer Ingelheim/Zealand Pharma), a once-weekly injectable medication, induced weight loss of up to 13% among adults with overweight or obesity without diabetes in the SYNCHRONIZE-1 trial. In new data from the SYNCHRONIZE-2 phase 3 trial presented at th
Retatrutide confers âsubstantialâ weight loss for adults with obesity, type 2 diabetes (opens the original)
Read excerpt
Once-weekly retatrutide induced weight loss of up to 18.8% at 80 weeks for adults with type 2 diabetes plus overweight or obesity, according to findings from the phase 3 TRIUMPH-2 trial. As Healio previously reported, adults with overweight or obesity without diabetes receiving once-weekly subcutaneous retatrutide (Eli Lilly) achieved weight loss of up to 25% at 80 weeks in the TRIUMPH-1 trial. In new data from TRIUMPH-2 presented at the European Association for the Study of Diabetes annual meet
Clinicians caring for midlife women need more menopause training (opens the original)
Read excerpt
Many healthcare professionals do not attribute symptoms such as fatigue, mood changes or sleep disruptions to menopause, leading to a missed opportunity for proper treatment in midlife women, according to a speaker. Jila Senemar, MD, FACOG, founder and chief medical officer of JilaMD, said healthcare professionals sometimes tend to be dismissive of menopause symptoms in women, despite the availability of therapies that may benefit that patient population. During a talk at the Women in Medicine S
FDA clears MODI, the first insulin dosing app for adults with type 2 diabetes (opens the original)
Read excerpt
The FDA has granted 510(k) clearance for an insulin titration algorithm that uses continuous glucose monitoring and insulin data to make dose adjustments for adults with type 2 diabetes, according to an industry press release. MODI (DreaMed Diabetes) is a mobile app designed to individualize insulin dosing for adults with type 2 diabetes. The app personalizes dose recommendations by analyzing the userâs CGM patterns and insulin information without the need for a healthcare professional to conf
Adults with type 1 diabetes can complete marathons with use of CGM, glucometer (opens the original)
Read excerpt
Adults with type 1 diabetes can safely complete marathons, according to data presented at the European Association for the Study of Diabetes annual meeting. In a small study assessing runners who competed in the 2025 Pozna Marathon in Poland, researchers found that all 10 runners with type 1 diabetes were able to finish the event with similar results as 10 controls without diabetes. However, the researchers found that continuous glucose monitoring measures differed from what was seen on glucomet
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For Healio, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.